SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced the closing of its private placement of redeemable convertible preferred stock and warrants resulting in initial gross proceeds of $28.0 million to…Read More
Telesis Bio Announces Closing of 280 Million Private Placement of Preferred Stock And Warrants to Purchase an Additional 462 Million of Common Stock
